Loading...

Anatara Lifesciences Ltd

ANR.AX•ASX
Healthcare
Biotechnology
A$0.007
A$0.001(16.67%)

Anatara Lifesciences Ltd (ANR.AX) Stock Overview

Explore Anatara Lifesciences Ltd’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 67.1/100

Key Financials

Market Cap1.5M
P/E Ratio-0.71
EPS (TTM)$-0.01
ROE-1.42%
Fundamental Analysis

AI Price Forecasts

1 Week$0.00
1 Month$0.01
3 Months$0.04
1 Year Target$0.07

ANR.AX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Anatara Lifesciences Ltd (ANR.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 66.42, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.07.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.71 and a market capitalization of 1.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

66.42RSI (14)
0.00MACD
20.14ADX
Revenue Growth
0.00%
Profit Growth
A$-0.01
↑ 28.27%
EPS Growth
A$-0.01
↑ 50.00%
Operating Margin
-775.12%
↑ 55.58%
ROE
-142.09%
↑ 28.27%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ANR.AXAnalyst Recommendations details for ANR.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.

CEO

David Lionel Brookes FACRRM, FAICD, MBBS

Headquarters

62 Lygon Street, Adelaide, VIC

Founded

2014

Frequently Asked Questions

;